EXAS earnings call for the period ending June 30, 2020.
News & Analysis: Exact Sciences
This cancer diagnostics company has produced one breakthrough product and is developing more.
Potential competitors for its colon cancer test Cologuard aren't ready for prime time.
Impressive long-term study results for an important product eased investor concerns over the tie-up between Exact Sciences and Genomic Health.
Shares are heading in opposite directions after the two cancer diagnostic companies surprised Wall Street by revealing plans to merge. Here's what investors need to know.
The biotech's recent momentum is showing no signs of cooling off, despite its jaw-dropping valuation.
Exact Sciences stock hit an all-time high last month, despite a sour market for biotech stocks.
Worries about Obamacare have taken a toll on shares of the diagnostics test company.
The diagnostics company's new marketing partner appears to be pulling its weight.
Shares of the molecular diagnostics company reverted to the mean last month, perhaps creating a tremendous buying opportunity for aggressive investors.
The molecular-diagnostics company's early look at Q4 and full-year 2018 revenue numbers revved up investors.